Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

25.16
-0.1300-0.51%
Post-market: 25.160.00000.00%19:30 EDT
Volume:1.78M
Turnover:44.85M
Market Cap:3.15B
PE:116.80
High:25.78
Open:25.64
Low:25.01
Close:25.29
52wk High:31.77
52wk Low:19.30
Shares:125.07M
Float Shares:111.18M
Volume Ratio:0.74
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:14.27
PE(LYR):-198.33

Loading ...

Arcutis Biotherapeutics Earnings Call Highlights Growth Momentum

TIPRANKS
·
Aug 12

Arcutis Biotherapeutics Rilis Transkrip Paparan Kinerja Kuartal II 2026

Reuters
·
Aug 12

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN)

TIPRANKS
·
Aug 11

Arcutis Biotherapeutics (ARQT) Could Be 31% Undervalued Following Profit And Higher Guidance

Simply Wall St.
·
Aug 10

Arcutis Biotherapeutics Grants 143,500 RSUs, 37,000 Stock Options to New Hires Under Inducement Plan

Reuters
·
Aug 08

Arcutis Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 08

Did Profitability, Higher 2026 Guidance, and New Commercial Leadership Just Recast Arcutis Biotherapeutics' (ARQT) Investment Narrative?

Simply Wall St.
·
Aug 06

Arcutis Biotherapeutics is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 06

Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities

TIPRANKS
·
Aug 06

Arcutis Biotherapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Arcutis Biotherapeutics Announces Key Commercial Leadership Changes

TIPRANKS
·
Aug 06

Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook

Reuters
·
Aug 06

Arcutis Biotherapeutics Q2 EPS $0.11 Beats $0.03 Estimate, Sales $129.861M Beat $118.852M Estimate

Benzinga Earnings
·
Aug 06

Arcutis Q2 Net Income Turns to USD 15 Million; Revenue Rises 59% Year over Year to USD 129.9 Million

Reuters
·
Aug 06

Arcutis Biotherapeutics: Raised Net Product Sales Guidance for the Full Year 2026 from $480 Million–$495 Million to $525 Million–$540 Million

THOMSON REUTERS
·
Aug 06

Arcutis Biotherapeutics Q2 Operating Expenses USD 113.432 Million

THOMSON REUTERS
·
Aug 06

Arcutis Biotherapeutics Inc Expected to Post Earnings of 4 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Earning Preview: Arcutis Biotherapeutics Inc. this quarter’s revenue is expected to increase by 61.29%, and institutional views are mostly bullish

Earnings Agent
·
Jul 29

Arcutis Biotherapeutics Director Christopher Peetz Files Initial Beneficial Ownership Statement

Reuters
·
Jul 18

Arcutis Biotherapeutics Director Howard G. Welgus Disposes of 4,730 Common Shares Worth $127,269.30

Reuters
·
Jul 18